Lung Infections Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025
The treatment for lung infections has conventionally been led by small molecule therapies. These therapies however, were aimed to treat the symptoms of lung infections, rather than the actual cause of the infection. This has led to the emergence of diverse treatment options, which differ in terms of their targets and their action mechanism. Many past cases exist, where a patient has been given a combination of drugs for the treatment of several lung issues. However, in recent times, the treatment options for lung infections have improved significantly This is in light of the extensive research and development carried by market players and contributed by government bodies. The extensive research in the field of lung infections treatment has led to the development of targeted therapies and novel therapies.
A key factor boosting the growth of the lung infections market is the decrease in the time for approval process of treatment drugs and therapies. This is encouraging more and more market players to come up with novel therapies and other treatment options, which in turn is boosting the growth of the lung infections market. Favorable reimbursement policies in many nations and an improvement in the healthcare infrastructure are helping the global lung infections market to grow even in the developing nations of Asia Pacific. A rise in the overall economy has led to an increase in the expenditure towards healthcare and this is also driving the demand for lung infections treatment options.
Lung infections are found in larger airways (bronchitis) or in smaller air sacs (pneumonia). In lung infections, pus and fluid get built up in the airways of the lung and make it difficult to breathe. They can affect people of all ages, but the elderly and the children are at high risk for developing lung infections. Etiologies for lung infections include virus, bacteria, and mycoplasma. Symptoms for lung infections include difficulty in breathing, fever, blue-colored lips, stomach pain, chest pain, headache, loss of appetite, and vomiting.
Common medical conditions that are caused primarily due to lung infections include asthma, chronic obstructive pulmonary disease, pneumonia, tuberculosis, lung cancer and cystic fibrosis. Lung infections can be diagnosed using blood tests, chest x-rays, chest magnetic resonance imaging, chest computed tomography scans, bronchoscopy and pulmonary function tests. Medication (antibiotics) and surgical treatment (lobectomy, chest tube insertion) are largely available across all regions to treat various lung infections.
The global geriatric population is growing at a rapid pace across and these people are at a high risk for developing lung infections. Thus, the rising geriatric population and growing prevalence of asthma, COPD, pneumonia and cystic fibrosis become the leading propellants of the global lung infections treatment market. The U.S. Census Bureau stated that the key segment of the U.S. population is geriatric demographic. According to the World Health Organization (WHO), the global geriatric population would increase from 524 mn in 2010 to around 2 bn by the end of 2050. The global geriatric population would grow also at a faster rate in developed countries such as the U.S., the U.K. and Japan.
Additionally, rising awareness among people about lung infections and successive technological advancements in diagnostic tests account for drivers of the global lung infections market. However, the market is currently being stifled by technological complexity and high costs associated with diagnostic procedures.
North America dominates the global lung infections market due to a strong demand for diagnostic tests and a growing demand for lung infection treatments. The region also holds a very high level awareness among people, further backed by government initiatives. Europe similarly represents the key share in the global lung infections treatment market, owing to the presence of an exceptionally large geriatric population.
Asia Pacific is considered as a largely untapped market for lung infections treatments due to a lower diagnosis rate and the lack of proper healthcare facilities in a few Asian countries. This market will be fuelled over the coming years by the swiftly evolving healthcare infrastructure and increase in healthcare expenditure. Asia Pacific also accounts as a promising region in lung infections treatment demand due to a rising market penetration of commercially available solutions. The rest of the world holds the fourth position in the global lung infections treatment market due to poor economic and health conditions in key countries.
Leading market players in the global lung infections market for 2016 included Bayer AG, Insmed Incorporated, Creative Antibiotics Sweden AB, and Destiny Pharma Ltd.
The study presents reliable qualitative and quantitative insights into:
The regional analysis covers:
The vast market research data included in the study is the result of extensive primary and secondary research activities. Surveys, personal interviews, and inputs from industry experts form the crux of primary research activities and data collected from trade journals, industry databases, and reputable paid sources form the basis of secondary research. The report also includes a detailed qualitative and quantitative analysis of the market, with the help of information collected from market participants operating across key sectors of the market value chain. A separate analysis of macro- and micro-economic aspects, regulations, and trends influencing the overall development of the market is also included in the report.
Highlights of the report:
Note: Immense care has been taken to present data with the highest levels of accuracy in all TMRResearch reports. Nevertheless, recent developments related to market/vendor landscape may take time to reflect in the analysis.
Flat 10% discount on Single User License if you prebook this report
Flat 10% discount on Multiple User License if you prebook this report
Flat 10% discount on Corporate License if you prebook this report